Table 4.
Multivariate Analysis of Factors Associated With 30-d Mortality
| Adjusted For The Propensity Score Matching For Combination Therapy | ||||
|---|---|---|---|---|
| No | Yes | |||
| Variables | P value | HR (95% CI) | P value | HR (95% CI) |
| Septic shock at infection onset | <.001 | 3.65 (2.27–5.87) | <.001 | 2.85 (1.65–4.92) |
| Charlson Comorbidity Index ≥ 3 | .005 | 2.42 (1.31–4.47) | .01 | 2.33 (1.22–4.48) |
| Dialysisa | .04 | 1.69 (1.03–2.78) | .02 | 1.91 (1.11–3.31) |
| COVID-19 | .03 | 1.64 (1.05–2.56) | .04 | 1.62 (1.19–2.63) |
| INCREMENT score ≥8 | .04 | 1.65 (1.02–2.67) | .01 | 2.02 (1.13–3.61) |
| MER-VAB started within 48 h of infection onset | .05 | 0.69 (0.55–1.06) | .39 | 0.81 (0.52–1.29) |
Abbreviations: CI, confidence interval; MER-VAB, meropenem-vaborbactam; HR, hazard ratio.